Breast Cancer Clinical Trials

Find Breast Cancer Clinical Trials Near You

Feasibility of Serial Multisite Image-Guided Biopsy To Study Breast Cancer Evolution

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients. Cancer biopsies are generally performed when cancer is diagnosed and are sometimes repeated when the cancer is suspected to have spread but this is not mandatory. However, studies have shown that cancers change with time and evolve to become resistant to therapy. The purpose of this study is to assess the feasibility of biopsies of multiple cancer sites across different time points during treatment and understand how cancers evolve and change throughout treatment. The findings of this study could pave the way for using cancer biopsies more frequently in the clinic to pick up changes in cancer behaviour that could influence treatment choice. The samples collected from this study will be used for molecular and genetic research to increase our understanding of how metastatic breast cancer changes during treatment and will enable us to develop new cancer treatments and new ways of monitoring response to cancer therapies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed locally advanced, inoperable breast cancer or metastatic breast cancer OR radiological evidence of metastatic disease with a high index of suspicion that this is a recurrence of a previously diagnosed breast cancer.

• Be aged 18 years and over.

• Have given written informed consent to participate.

Locations
Other Locations
United Kingdom
Royal Marsden NHS Foundation Trust
RECRUITING
London
Contact Information
Primary
Sophie Cooke
FORTITUDE@rmh.nhs.uk
02034373610
Time Frame
Start Date: 2026-02-23
Estimated Completion Date: 2040-04
Participants
Target number of participants: 200
Related Therapeutic Areas
Sponsors
Leads: Royal Marsden NHS Foundation Trust

This content was sourced from clinicaltrials.gov